Browse the evidence

Cohort unrepresentativeness in the UK Biobank leads to an underestimation of the mortality risk associated with the least healthy cumulative lifestyle profiles.

If you have an unhealthy lifestyle (poor diet, low activity, smoking), the risk to your life is likely higher than general statistics suggest. Correcting for population biases shows a 9% increase in mortality risk for the least healthy groups. Prioritize improving these factors to mitigate this hidden risk.

For early chronotypes (morning types), rotating night shift work increases type 2 diabetes risk as the duration of exposure increases, whereas for late chronotypes (evening types), daytime work schedules are associated with significantly higher diabetes risk compared to those working night shifts.

If you are a 'morning person' (early chronotype), long-term rotating night shifts significantly increase your type 2 diabetes risk. If you are a 'night owl' (late chronotype), working day shifts is actually riskier for your metabolism than working night shifts. Align your work schedule with your natural sleep preference to minimize metabolic risk.

South Asian and Aboriginal Canadian populations exhibit an unfavorable adipokine profile characterized by lower adiponectin and higher leptin levels compared to European and Chinese Canadians, which is associated with greater insulin resistance.

If you are of South Asian or Aboriginal descent, your body may naturally produce less adiponectin (a hormone that improves insulin sensitivity) and more leptin than other ethnic groups, even at the same weight. This makes you more prone to insulin resistance. Focus on managing your glycemic load (sugar and refined carb intake) to help mitigate this specific metabolic risk.

High glycemic index diets cause a larger decrease in adiponectin and a larger increase in insulin resistance in South Asian and Aboriginal populations compared to European and Chinese populations.

For South Asian and Aboriginal individuals, consuming foods with a high glycemic index (refined carbs, sugars) triggers a sharper drop in protective adiponectin and a sharper rise in insulin resistance than it does for Europeans. Prioritizing low-glycemic, high-fiber carbohydrates is a key strategy to manage metabolic health in these groups.

Whole grain intake is not significantly associated with cancer mortality, and substituting whole grains for refined grains or red meat does not significantly reduce cancer mortality.

Do not rely on whole grains alone to prevent cancer. While they are excellent for heart health and overall longevity, this study found no significant link to reduced cancer mortality. Maintain a balanced diet with various vegetables and fruits for cancer prevention, while using whole grains for cardiovascular benefits.

Treatment with the selective beta3-adrenoceptor agonist CL 316,243 increases insulin-mediated glucose disposal (IMGD) and fat oxidation in lean human males, without altering energy expenditure or body weight.

Taking CL 316,243 (1,500 mg/day) for 8 weeks improves how your body handles insulin and increases the amount of fat you burn during the day, even without changing your total calorie burn or losing weight. This effect is strongest in lean individuals and depends on maintaining the drug's presence in your blood.

Overall dietary patterns (AHEI, DASH, AHA 2020, Biologic) are not associated with the risk of incident heart failure in older adults, although higher sodium intake is associated with an increased risk.

Focus less on strict adherence to specific 'healthy' diet patterns (like DASH or AHEI) for heart failure prevention, and more on physical activity, not smoking, and maintaining a healthy weight. However, be mindful of sodium intake, as high levels were linked to increased risk.

Increasing fat availability before exercise (via high-fat diet or fat infusion) reduces carbohydrate utilization but does not improve exercise performance.

Do not rely on high-fat diets or fat infusions to improve your endurance performance. While it changes how your body burns fuel (less carbs, more fat), it does not make you faster and may even make you slower compared to a high-carb diet.

Higher plasma levels of trans-18:2 fatty acids (derived from linoleic acid) are associated with a significantly increased risk of fatal ischemic heart disease and sudden cardiac death in older adults.

Focus on minimizing the heat treatment of polyunsaturated oils (like soybean, corn, sunflower) as this process generates trans-18:2 fatty acids, which are linked to higher heart disease risk. While industrial trans fats are largely removed, the specific trans-18:2 isomer formed during refining and frying remains a concern. Prioritize oils with low trans-18:2 content or unrefined options where possible.

Oral administration of deuterated creatine (D3-creatine) allows for the accurate estimation of total body skeletal muscle mass via urine D3-creatinine enrichment, providing a method with less bias than DXA or 24-hour urine creatinine excretion.

To accurately measure total skeletal muscle mass, the D3-creatine dilution method is superior to DXA and standard urine creatinine tests. It involves taking a single oral dose of deuterated creatine and collecting urine for 5 days to measure isotopic enrichment. This method correlates strongly with MRI (r=0.868) and avoids the overestimation errors of DXA caused by body water fluctuations. It is currently a research tool, not a standard clinical test.

Obese individuals with type 2 diabetes exhibit significantly lower expression of key adipogenic genes (SREBP1c, STAT5A, PPARγ2) in subcutaneous adipose tissue compared to obese non-diabetic individuals, which is associated with larger fat cell size and reduced insulin sensitivity.

For obese individuals with type 2 diabetes, the body's ability to create new fat cells (adipogenesis) is impaired compared to obese individuals without diabetes. This leads to existing fat cells becoming larger (hypertrophy), which is strongly linked to insulin resistance. The focus should be on improving metabolic health and insulin sensitivity, as this may support healthier fat storage dynamics.

Individuals with metabolically healthy obesity (MHO) do not significantly improve their cardiovascular and metabolic risk profiles through standard weight loss interventions (lifestyle, pharmacological, or bariatric surgery) compared to metabolically unhealthy obese individuals.

If you are obese but metabolically healthy (normal blood pressure, sugar, and lipids), standard weight loss programs may not improve your metabolic health further and might even temporarily worsen insulin sensitivity. Your focus should be on maintaining your current metabolic health and addressing non-metabolic issues like joint pain or fitness, rather than expecting weight loss to 'cure' your metabolic profile.

Metabolically healthy obesity (MHO) is a transient phenotype that often transitions to metabolically unhealthy obesity with aging, and MHO individuals still face increased risks for heart failure and non-metabolic comorbidities.

Being 'metabolically healthy' now does not mean you are immune to future metabolic disease. Your risk of developing diabetes or heart issues increases as you age, even if you are currently healthy. Regular monitoring and maintaining a healthy lifestyle are essential to delay or prevent this transition.

Mutations in the coding sequence of the human OB (leptin) gene are not a common cause of obesity in humans, despite causing obesity in mice.

This research suggests that for the vast majority of people with obesity, the cause is not a simple, single-gene mutation in the leptin pathway. This implies that lifestyle interventions (diet and exercise) are still relevant and potentially effective, as the biological machinery for regulating weight is likely intact, even if dysregulated by other factors.

Obese individuals have less brown adipose tissue mass and activity than lean individuals, which may contribute to obesity susceptibility.

Obese individuals tend to have less active brown fat, but it is unclear if restoring it would lead to weight loss.

Vitamin E supplementation (1200 IU/day for 30 days) does not attenuate contraction-induced muscle damage, torque deficits, or inflammatory cell infiltration following eccentric exercise in healthy young men.

If you are doing heavy eccentric training (like downhill running or heavy lifting), taking 1200 IU of Vitamin E daily for a month will not reduce your muscle soreness, strength loss, or inflammation. You can skip the supplement for this purpose as it offers no protective benefit over placebo for muscle damage indices.

Disuse-induced muscle atrophy in humans is primarily driven by a sustained reduction in muscle protein synthesis (MPS) rather than an increase in muscle protein breakdown (MPB).

To prevent muscle loss during periods of inactivity (like injury recovery or bed rest), simply moving minimally is often insufficient to maintain normal synthesis rates. The primary driver of atrophy is the shutdown of muscle building processes. While you cannot always force training, understanding that synthesis drops significantly (40-50%) highlights why even minimal, involuntary movement or specific nutritional strategies (like amino acid provision, though noted as blunted) are critical to counteract this specific metabolic shutdown.

Immobilization induces rapid muscle insulin resistance (MIR) within 3-5 days, which may contribute to the dysregulation of protein metabolism, although a direct causal link to atrophy is not fully established.

During periods of immobilization, your muscles become resistant to insulin within days. This hormonal shift likely contributes to the shutdown of muscle building. While you cannot always avoid immobilization, understanding this link highlights why metabolic health and potentially minimal movement (to stimulate glucose uptake) are important considerations alongside nutrition.

In preclinical rodent models, disuse atrophy involves both decreased protein synthesis and increased protein degradation, with the extent of degradation being muscle-specific and dependent on fiber type.

While rodent studies show that muscle breakdown increases during disuse, human studies suggest this is not the primary driver. This highlights the importance of not blindly applying animal research to human health advice. For humans, maintaining synthesis (via minimal movement/nutrition) is likely more critical than worrying about breakdown rates.

Obesity should be clinically classified as a chronic, progressive, and relapsing disease rather than a lifestyle choice or mere risk factor, which is necessary to combat stigma and promote effective long-term management.

Understand that obesity is a chronic medical condition, not a character flaw. This means it requires long-term management strategies similar to other chronic diseases like hypertension or diabetes, rather than short-term 'fixes' based on willpower. Seek care from providers who view it as a disease to manage, not a failure to overcome.

SGLT2 inhibitors (specifically empagliflozin) reduce cardiovascular mortality and heart failure hospitalization rates in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have Type 2 Diabetes and existing heart disease, empagliflozin (an SGLT2 inhibitor) significantly lowers your risk of dying from heart causes and being hospitalized for heart failure. This benefit happens regardless of how much your blood sugar drops, suggesting it protects the heart directly. While side effects like genital infections are possible, the life-saving benefits for high-risk patients are substantial. This drug class is also being studied for heart failure patients without diabetes.

The metabolically healthy obese (MHO) phenotype is characterized by preserved insulin sensitivity and favorable metabolic markers despite high body fat, primarily driven by reduced visceral and ectopic (liver) fat accumulation and healthy adipose tissue expansion.

If you are obese but metabolically healthy (normal blood pressure, lipids, and insulin sensitivity), your risk profile is significantly better than that of an obese person with metabolic abnormalities. Focus on maintaining this metabolic health through healthy lifestyle habits, as MHO is not a permanent state and conversion to unhealthy status occurs in ~30% of cases over 5-10 years, often due to aging or weight gain.

Preserved mitochondrial function and healthy adipose tissue expansion (via angiogenesis and adiponectin secretion) are key mechanisms that prevent ectopic fat storage and insulin resistance in metabolically healthy obese individuals.

Maintaining healthy adipose tissue function through regular physical activity and avoiding excessive weight gain may help preserve mitochondrial health and prevent the shift from metabolically healthy to unhealthy obesity.

Acute damaging muscle-lengthening contractions trigger a temporal sequence of IGF-1 splice variant expression in human skeletal muscle, where Mechano Growth Factor (MGF) peaks early (24h) correlating with satellite cell proliferation markers (Myf5/MyoD), while IGF-1Ea and IGF-1Eb peak later (72h) correlating with differentiation markers (MRF4/myogenin).

This research highlights that muscle repair after intense exercise (like heavy eccentric training) relies on local molecular signals rather than blood hormone levels. Specifically, the body produces a variant called MGF early on (around 24 hours) to kickstart satellite cell proliferation, followed by other IGF variants (Ea/Eb) later (around 72 hours) to help cells differentiate and repair. For training, this implies that sufficient mechanical damage is required to trigger this specific local molecular cascade, and that recovery time allows these distinct phases to occur.